Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for LENSAR, Inc. (LNSR : NSDQ)

• Company Description    LENSAR Inc. is a commercial-stage medical device company. It focuses on designing, developing and marketing an advanced femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. LENSAR Inc. is based in Orlando, Florida. Number of Employees: 140

• Price / Volume Information    Yesterday's Closing Price: $13.11 Daily Weekly Monthly 20 Day Moving Average: 146,223 shares Shares Outstanding: 11.79 (millions) Market Capitalization: $154.60 (millions) Beta: 0.50 52 Week High: $17.31 52 Week Low: $3.50 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 4.88% 0.95% 12 Week -5.75% -20.72% Year To Date 46.64% 37.33%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 2800 Discovery Drive - Orlando,FL 32826 USA ph: 888-536-7271 fax: - ir.contact@lensar.com http://www.lensar.com

• General Corporate Information    Officers Nicholas T. Curtis - Chief Executive Officer and Director William J. Link - Chairperson of the Board of Directors Thomas R. Staab, II - Chief Financial Officer Thomas B. Ellis - Director Todd B. Hammer - Director Peer Information LENSAR, Inc. (ABMD) LENSAR, Inc. (DMDS) LENSAR, Inc. (CPWY.) LENSAR, Inc. (EQUR) LENSAR, Inc. (ECIA) LENSAR, Inc. (FMS) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED INSTRUMENTS Sector: Medical CUSIP: 52634L108 SIC: 3841 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/14/25 Share - Related Items Shares Outstanding: 11.79 Most Recent Split Date: (:1) Beta: 0.50 Market Capitalization: $154.60 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/14/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: 2.71 EPS Growth vs. Year Ago Period: -1,121.05% vs. Previous Quarter: -44.10% Sales Growth vs. Year Ago Period: 33.73% vs. Previous Quarter: -15.37% ROE 06/30/25 - - 03/31/25 - -737.30 12/31/24 - -137.01 ROA 06/30/25 - - 03/31/25 - -81.69 12/31/24 - -44.49 Current Ratio 06/30/25 - - 03/31/25 - 1.81 12/31/24 - 2.80 Quick Ratio 06/30/25 - - 03/31/25 - 1.25 12/31/24 - 2.04 Operating Margin 06/30/25 - - 03/31/25 - -94.01 12/31/24 - -53.20 Net Margin 06/30/25 - - 03/31/25 - -99.17 12/31/24 - -58.71 Pre-Tax Margin 06/30/25 - - 03/31/25 - -99.17 12/31/24 - -58.71 Book Value 06/30/25 - - 03/31/25 - -1.88 12/31/24 - 0.42 Inventory Turnover 06/30/25 - - 03/31/25 - 2.00 12/31/24 - 1.78 Debt-to-Equity 06/30/25 - - 03/31/25 - - 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - - 12/31/24 - 0.00

Powered by Zacks Investment Research ©